A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Registry ID

EUCTR2014-004334-26

Source registry

EUCTR

Phase

PHASE3

Sponsor

UCB Japan Co. Ltd

Last update

2026-08-16

Conditions

• Epilepsies Partial

Summary

The primary objective was to continuously evaluate the safety of long-term administration at the dose range from LEV 500 mg/day to LEV 3000 mg/day in subjects who completed N01221 or N01020.

View on source registry